Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
06/2003
06/03/2003USRE38133 Kappa agonist compounds and pharmaceutical formulations thereof
06/03/2003US6573376 Solvent extraction; plant extracts
06/03/2003US6573364 Isolation and characterization of Hermansky Pudlak Syndrome (HPS) protein complexes and HPS protein-interacting proteins
06/03/2003US6573287 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
06/03/2003US6573285 Method for preventing or treating pain by administering an endothelin antagonist
06/03/2003US6573283 Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-3H-6,9-dioxa-1,3-diazacyclopenta[a]naphthalene
06/03/2003US6573281 Its pharmaceutically acceptable salts for the treatment or prevention of adaptation disorders, bipolar disorders, and dysthymic disorders.
06/03/2003US6573278 Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases
06/03/2003US6573265 Preventing or treating diseases caused by free radicals of the cellular oxygen metabolism, stimulating nerve cell growth, antagonizing glutamate receptors and/or stimulating the growth notably of glutamergic nerve cells; anticarcinogenic agents;
06/03/2003US6573263 For improving perception, concentration power, learning power and/ or memory power
06/03/2003US6573259 Inhibitors of interleukin-1β converting enzyme
06/03/2003US6573255 Vitamin D analogues
06/03/2003US6573243 Pompilid wasp-derived neuropeptides
06/03/2003US6573236 Myelin oligodendrocyte glycoprotein (MOG) polypeptide-specific antibody to bind a natural MOG polypeptide and competitively inhibit the binding of an autoantibody, does not comprise functional Fc portion; multiple sclerosis
06/03/2003US6573095 Polynucleotides isolated from skin cells
06/03/2003US6573067 Nucleic acid encoding sodium channels in dorsal root ganglia
06/03/2003US6572879 Formulations for transdermal delivery of pergolide
06/03/2003US6572853 Recombinant human beta interferon with enhanced solubility
06/03/2003US6572638 Method of controlling body temperature while inhibiting thermoregulatory responses
06/03/2003CA2413491A1 Treatment for ischemic stroke
06/03/2003CA2354880C Method for the preparation of citalopram
06/03/2003CA2273446C Piperidones
06/03/2003CA2103906C Iloprost with action against cerebral malaria
05/2003
05/30/2003WO2003044524A2 Methods and means for influencing intracellular communication and intracellular organelle transport
05/30/2003WO2003044196A1 Postsynaptic proteins
05/30/2003WO2003044184A1 Treatment of pml targeting jc virus agno
05/30/2003WO2003044170A2 Cyclic amp phosphodiesterase 4d7 isoforms and methods of use
05/30/2003WO2003044162A2 Genes encoding g-protein coupled receptors and methods of use therefor
05/30/2003WO2003044057A2 Use of obg3 for promoting central nervous system remyelination
05/30/2003WO2003044024A1 4-(oxazolopyridin-2-yl)-1,4-diazabicyclo-[3.2.2]nonane derivatives, preparation and therapeutic use thereof
05/30/2003WO2003044021A2 Substituted indolizine-like compounds and methods of use
05/30/2003WO2003044020A1 4-(1,3,4-thiadiazol-2-yl)-1,4-diazabicyclo-[3.2.2]nonane derivatives, preparation and therapeutic use thereof
05/30/2003WO2003044019A1 4-(oxadiazol-3-yl)-1,4-diazabicyclo[3.2.2]-nonane derivatives, preparation and therapeutic use thereof
05/30/2003WO2003044018A1 1h-pyrrolo[3,2-b]pyridine-3-carboxylic acid amides
05/30/2003WO2003044017A1 Beta 3 adrenergic agonists
05/30/2003WO2003044015A2 Substituted heteroarylalkanoic acids and their use as aldose reductase inhibitors
05/30/2003WO2003044010A1 Nitrogenous tetrahydropyridyl-alkyl-heterocycles with tnf activity
05/30/2003WO2003044009A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
05/30/2003WO2003044006A1 Substituted benzopyrans as selective estrogen receptor-beta agonists
05/30/2003WO2003044000A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
05/30/2003WO2003043999A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
05/30/2003WO2003043991A1 Heteroaryl carboxylic acid amides
05/30/2003WO2003043988A1 Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient
05/30/2003WO2003043987A2 (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease
05/30/2003WO2003043985A1 Heterocyclic compounds and methods of use
05/30/2003WO2003043981A1 2-(3-sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors
05/30/2003WO2003043980A1 Azetidinyl diamines useful as ligands of the nociceptin receptor orl-1
05/30/2003WO2003043975A1 Amine 1,2- and 1,3-diol compounds and their use for treatment of alzheimer's disease
05/30/2003WO2003043974A2 New pharmaceutical compounds
05/30/2003WO2003043657A1 Topical delivery of codrugs
05/30/2003WO2003043651A1 Drug mobilizing pluripotent stem cells from tissue into peripheral blood
05/30/2003WO2003043640A2 Treatment of major depressive disorder using glucocorticoid receptor antagonists
05/30/2003WO2003043639A2 PHARMACEUTICAL COMPOSITION COMPRISING A ClC-2 CHANNEL OPENER
05/30/2003WO2003043636A1 Nicotin-or isonicotin benzothiazole derivatives
05/30/2003WO2003043634A1 Benzothiazole derivatives as adenosine receptor ligands
05/30/2003WO2003043618A2 Amino diols useful in the treatment of alzheimer's disease
05/30/2003WO2003043617A1 Compositions and kits comprising a defined boron compound, methods of their preparation, and use and administration thereof
05/30/2003WO2003043613A2 Use of glycosides of mono- and diacylglycerol as anti-inflammatory agents
05/30/2003WO2003043612A1 Micronized film-forming powder comprising an active substance
05/30/2003WO2003043608A1 Process for the preparation of tablets comprising s-adenosylmethionine
05/30/2003WO2003043583A2 Treatment of immunological disorders using anti-cd30 antibodies
05/30/2003WO2003016917A3 Sodium channel regulators and modulators
05/30/2003WO2003013442A3 Catechins for the treatment of fibrillogenesis in alzheimer's disease, parkinson's disease, systemic aa amyloidosis, and other amyloid disorders
05/30/2003WO2003008448A3 Novel human proton-gated channels
05/30/2003WO2003005998A3 A pharmaceutical composition comprising a nicotinic receptor partial antagonist and an antiemetic agent of modulating cholinergic function
05/30/2003WO2002100328A3 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels
05/30/2003WO2002096952A3 Conjugate of a transport protein and a protein for modulation of notch signalling
05/30/2003WO2002096363A3 Method for treating fibrotic diseases or other indications
05/30/2003WO2002088100A3 Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
05/30/2003WO2002066040A3 Sensitization of chemotherapeutic agent resistant neoplastic cells with reovirus
05/30/2003WO2002062795A3 Dihydropyrazolopyridine compounds and pharmaceutical use thereof
05/30/2003WO2002051868A3 Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
05/30/2003WO2002051415B1 Use of sequestrants for treating prion diseases
05/30/2003WO2002041839A3 Assays for inhibitors of neuronal transport of alzheimer's amyloid precursor protein
05/30/2003WO2002036816A3 Method of determining susceptibility to diseases
05/30/2003WO2002036148A3 Use of death receptor ligands or rip to initiate the non-caspase-dependent cell death and compounds for inhibition of the non-caspase-dependent cell death
05/30/2003WO2002036116A9 Tripeptidyl peptidase inhibitors
05/30/2003WO2002016313A3 Integrin receptor inhibitors
05/30/2003CA2492536A1 Postsynaptic proteins
05/30/2003CA2468018A1 Micronized film-forming powder comprising an active substance
05/30/2003CA2467930A1 Treatment of pml targeting jc virus agno
05/30/2003CA2467798A1 Amine 1,2- and 1,3-diol compounds and their use for treatment of alzheimer's disease
05/30/2003CA2467752A1 Piperidin-2-one derivative compounds and pharmaceutical composition comprising the same as active ingredient
05/30/2003CA2467749A1 (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease
05/30/2003CA2467559A1 Topical delivery of codrugs
05/30/2003CA2467557A1 Agent which mobilizes multipotential stem cells from tissues to peripheral blood
05/30/2003CA2467551A1 Benzothiazole derivatives as adenosine receptor ligands
05/30/2003CA2467542A1 1h-pyrrolo[3,2-b]pyridine-3-carboxylic acid amides
05/30/2003CA2467476A1 Amino diols useful in the treatment of alzheimer's disease
05/30/2003CA2467242A1 Treatment of immunological disorders using anti-cd30 antibodies
05/30/2003CA2467206A1 Genes encoding g-protein coupled receptors and methods of use therefor
05/30/2003CA2467166A1 New pharmaceutical compounds
05/30/2003CA2466925A1 Substituted heteroarylalkanoic acids and their use as aldose reductase inhibitors
05/30/2003CA2466733A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
05/30/2003CA2466491A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
05/30/2003CA2466072A1 Substituted indolizine-like compounds and methods of use
05/30/2003CA2463790A1 Cyclic amp phosphodiesterase 4d7 isoforms and methods of use
05/29/2003US20030101003 Methods for representing sequence-dependent contextual information present in polymer sequences and uses thereof
05/29/2003US20030100772 Oxygen-containing heterocyclic compounds
05/29/2003US20030100770 D-proline derivatives
1 ... 1209 1210 1211 1212 1213 1214 1215 1216 1217 1218 1219 1220 1221 1222 1223 1224 1225 1226 1227 1228 1229 ... 1833